2024
Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States
Potnis K, Ito S, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States. Blood 2024, 144: 3644. DOI: 10.1182/blood-2024-204312.Peer-Reviewed Original ResearchSevere aplastic anemiaTreatment of severe aplastic anemiaQuality-adjusted life yearsAplastic anemiaIncremental net monetary benefitDeterministic sensitivity analysisProbabilistic sensitivity analysesImmunosuppressive therapyNewly diagnosed severe aplastic anemiaCost-effectiveness of eltrombopagOral thrombopoietin receptor agonistPatients treated with eltrombopagUntreated severe aplastic anemiaHematopoietic stem cell transplantationCost-effective therapeutic strategyDevelopment of adverse eventsLonger-term follow-up dataRACE trialsLater-line therapyThrombopoietin receptor agonistsPhase I/II trialSecond-line therapyStem cell transplantationU.S. payer perspectiveFirst-line treatment
2018
The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013
Tsai DE, Bagley S, Reshef R, Shaked A, Bloom RD, Ahya V, Goldberg L, Chung A, Debonera F, Schuster SJ, Huntington SF. The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013. American Journal Of Hematology 2018, 93: 874-881. PMID: 29659047, DOI: 10.1002/ajh.25116.Peer-Reviewed Original ResearchConceptsPosttransplant lymphoproliferative disorderEBV serostatusMonomorphic histologyPTLD casesLymphoproliferative disordersMonomorphic posttransplant lymphoproliferative disorderPolymorphic posttransplant lymphoproliferative disordersTime of transplantTacrolimus useImmunosuppressive regimensImmunosuppressive therapyTransplant patientsTransplant recipientsClinical managementDifferent prognosisOPTN databaseOrgan transplantationDifferent malignanciesHistologyLate occurrenceSerostatusTransplantPotential causesTherapyDisorders